Familial Mediterranean Fever

Familial Mediterranean Fever

National Organization for Rare Disorders, Inc.


It is possible that the main title of the report Familial Mediterranean Fever is not the name you expected. Please check the synonyms listing to find the alternate name(s) and disorder subdivision(s) covered by this report.


  • FMF
  • familial paroxysmal polyserositis
  • recurrent polyserositis

Disorder Subdivisions

  • familial Mediterranean fever type 1
  • familial Mediterranean fever type 2

General Discussion


Familial Mediterranean fever (FMF) is an inherited autoinflammatory disease characterized by recurrent episodes (attacks) of fever and acute inflammation of the membranes lining the abdomen, joints, and lungs. In some cases, affected individuals may develop skin rashes (erysipelas like erythema) affecting the lower legs. Less often, inflammation of the membrane lining the heart or covering the brain and spinal cord may occur. Some individuals may develop a serious condition known as amyloidosis, in which certain proteins called amyloid accumulates in various tissues of the body. In FMF, amyloid accumulates in the kidneys (renal amyloidosis) where it can impair kidney function potentially result in life-threatening complications such as kidney failure. The specific symptoms and severity of FMF are highly variable. Some individuals develop amyloidosis, but none of the other symptoms associated with FMF. These cases are sometimes referred to as FMF type 2. FMF is caused by mutations of the pyrin (MEFV) gene and is inherited as an autosomal recessive trait.


FMF is classified as an autoinflammatory syndrome. Autoinflammatory syndromes are a group of disorders characterized by recurrent episodes of inflammation due to an abnormality of the innate immune system. They are not the same as autoimmune syndromes, in which the adaptive immune system malfunctions and mistakenly attacks healthy tissue. FMF is the most common autoinflammatory syndrome. It is also classified as a hereditary periodic fever syndrome.


The symptoms and severity of FMF can vary greatly from one person to another, even among members of the same family. The classic form of FMF is characterized by short, recurrent episodes (attacks) of inflammation. These episodes often occur without warning and can last anywhere from 1 to 4 days. The duration and severity of episodes (both in different people and even the same person) are not consistent. In between episodes, affected individuals are usually symptom-free and feel normal. The amount of time between episodes will vary and can range from a week to a few months. In many cases, the initial episode occurs in infancy or early childhood. Most affected individuals experience their initial episode before the age of 20.

Approximately 50 percent of individuals with FMF experience a sensation of poor health or unpleasantness that precedes the onset of an episode of FMF. This is referred to as a prodrome or prodromal phase. Attacks can be triggered by fatigue, stress or physical effort.

Recurrent fevers during early childhood are often the initial symptom of FMF. Temperatures can rise rapidly often spiking to 100-104 degrees Fahrenheit (or up to >40 degrees Celsius). Episodes of fever can occur alone or in association with any or all of the symptoms discussed below. During mild episodes, fevers may occur without additional symptoms. In some individuals, recurrent fevers during childhood can be the only symptom associated with FMF.

Along with chronic episodes of fever, serositis is another common symptom of FMF. Serositis refers to inflammation of various serous tissues of the body. Serous tissues include the membranes that line the abdomen, lungs, and heart.

Approximately 90 percent of individuals with FMF experience abdominal symptoms that can range from mild bloating to inflammation of the lining of the abdomen (peritonitis). Abdominal symptoms can coincide with the onset of fever. Abdominal pain or tenderness is common and the abdominal muscles are often noticeably rigid and tight, sometimes described as "board-like." The abdomen is often swollen (distended). Some individuals may develop constipation during an abdominal episode, sometimes followed by diarrhea after an episode ends. Affected individuals are often misdiagnosed as having acute abdomen (peritonitis) and may undergo unnecessary surgery.

Approximately 75 percent of affected individuals experience joint pain (arthralgia) and inflammation (arthritis) due to inflammation of the membrane (synovium) lining the joints. Pain, which can be accompanied by swelling, can be severe. During an episode, the range of motion of affected joints can be limited. Episodes of arthritis can begin suddenly and usually subside within 7 days. Joint function usually returns to normal after an episode ends. However, in some cases, these joint issues can continue for several weeks or months. In some cases, episodes are triggered by minor trauma or sustained exertion such as prolonged walking. Most episodes involve one of the large joints of the leg (i.e., knee, ankle or hip). In rare cases, recurrent arthritis of one joint can be the only symptom of FMF.

Some affected individuals may also experience chest pain due to inflammation of the thin membrane (pleura) that lines the lungs (pleuritis). Episodes usually appear suddenly and resolve quickly within 48 hours. Affected individuals can experience painful breathing and diminished breathing sounds on the affected side of the lungs. Shortness of breath and rapid, shallow breathing may also occur.

Some individuals with FMF may develop a potentially serious complication known as amyloidosis. Amyloidosis is characterized by the accumulation of a fatty-like substance called amyloid in various parts of the body. In FMF, amyloid accumulates in the kidneys (renal amyloidosis), impairing kidney function. Renal amyloidosis can eventually progress to cause kidney failure. The prevalence of amyloidosis varies based upon ethnicity, gender and the specific mutation of the MEFV gene. Certain ethnic populations including individuals of Turkish or Sephardic Jewish descent have a relatively high incidence of amyloidosis when compared to individuals from other ethnic groups. Individuals with FMF type 2 develop amyloidosis, but none of the other symptoms associated with FMF.

Some individuals with FMF have painful, swollen and bright red (erythematous) skin lesions on the lower legs. These lesions resemble a skin infection called erysipelas. They may be warm or hot to the touch and most often occur between the ankle and the knee.

Less often, additional symptoms can affect individuals with FMF including inflammation of the sac-like membrane (pericardium) lining the heart (pericarditis). Pericarditis may be associated with pain behind the breastbone (sternum) that is worse upon swallowing. Inflammation of the membranes (meninges) lining the brain and spinal cord (meningitis) may also occur and may cause headaches. Headaches may also occur independent of meningitis.

Another occasional symptom associated with FMF is muscle pain (myalgia), which is often severe and can be widespread (diffuse) and disabling. Along with fever, myalgia can occur with abdominal and joint pain and diarrhea. Myalgic episodes can last for a short time or longer, even up to six to eight weeks (protracted febrile myalgia).

Untreated individuals with FMF have a risk of infertility. Individuals with severe FMF characterized by multiple frequent episodes and/or amyloidosis are particularly at risk if untreated. In males, inflammation of the testes (orchitis) may also occur. Orchitis is characterized by pain, redness and swelling.

Enlargement of the spleen can also occur (splenomegaly) and is quite frequent in children.

According to the medical literature, some individuals with FMF have an increased risk of developing additional inflammatory disorders, especially those characterized by inflammation of the blood vessels (vasculitides), including Bechet's disease, polyarteritis nodosa, and Henoch-Schonlein purpura. Affected individuals may also have at greater risk of developing ulcerative colitis, Crohn's disease and rheumatoid arthritis. (For more information on these disorders, choose the specific disorder name as your search term in the Rare Disease Database.)


FMF is caused by mutations of the MEFV gene. The disease is inherited as an autosomal recessive trait. Hereditary diseases are determined by the combination of genes for a particular trait that are on the chromosomes received from the father and the mother.

Recessive genetic disorders occur when an individual inherits the same abnormal gene for the same trait from each parent. If an individual receives one normal gene and one gene for the disease, the person will be a carrier for the disease, but usually will not show symptoms. The risk for two carrier parents to both pass the defective gene and, therefore, have an affected child is 25 percent with each pregnancy. The risk to have a child who is a carrier like the parents is 50 percent with each pregnancy. The chance for a child to receive normal genes from both parents and be genetically normal for that particular trait is 25 percent. The risk is the same for males and females.

Although FMF is an autosomal recessive disorder, some individuals who inherited only one abnormal gene (heterozygotes) will develop symptoms of inflammatory disease very similar to FMF. These individuals are also a greater risk than the general population of developing other inflammatory diseases such as Bechet's disease and Crohn's disease. The severity of the disease in these individuals is often similar to individuals who inherited two disease genes (homozygotes) or individuals with two different mutations (compound heterozygotes), and these individuals usually require treatment (see Standard Therapies below). The reason that some individuals with one mutated gene develop symptoms is not fully understood. More research is necessary to determine why this occurs and whether there is a specific disease pattern associated with these cases.

Investigators have determined that the MEFV gene is located on the short arm (p) of chromosome 16 (16p13.3). More than 220 different mutations of the MEFV gene have been identified, although only four are clearly pathogenic. The MEFV gene contains instructions for creating (encoding) a protein known as pyrin. Mutations of the MEFV gene lead to deficient levels of functional pyrin. The exact role of pyrin in the body is not known. Researchers believe that pyrin is critical for the proper function of the innate immune system by regulating or inhibiting the body's inflammatory response. Recent research suggests that a mutation of the MEFV gene results in excessive release of interleukin-1B. Interleukin-1B is a pro-inflammatory cytokine (a specialized protein secreted from certain immune system cells that either stimulates or inhibits the function of other immune system cells). Drugs that inhibit the activity of interleukin-1B may have a role in treating FMF (see Investigational Therapies section below).

Although episodes of FMF can occur spontaneously for no identifiable reason, certain triggers have been identified in some cases. These triggers include infection, trauma, vigorous exercise, and stress. In women, onset of their period (menses) can trigger an episode.

Affected Populations

FMF affects males and females in equal numbers, although some studies suggest a slight male preponderance. FMF can affect individuals of any ethnic group, but the rates are much higher for certain Mediterranean populations including individuals of Armenian, Turkish, Arabic and North African Jewish descent. In these populations, the prevalence is estimated to be 1 in 200.

Standard Therapies


A diagnosis of FMF is based upon identification of characteristic symptoms, a detailed patient history, a thorough clinical evaluation and a variety of specialized tests. These tests can aid in obtaining a diagnosis of FMF or in assessing the extent of the disorder. Prompt diagnosis in FMF is important to avoid misdiagnosis and unnecessary surgery (as many children are misdiagnosed as having appendicitis).

Clinical Testing and Work-Up

During an episode, a blood test known as an erythrocyte sedimentation rate may be performed. Sedimentation rate measures how long it takes red blood cells (erythrocytes) to settle in a test tube over a given period. Many individuals with FMF have an elevated sedimentation rate, which is an indication of inflammation. Blood tests can also reveal elevated levels white blood cell levels, which are indicative of an immune system response, elevated C-reactive protein, which is elevated during periods of inflammation, and/or elevated levels of fibrinogen (a substance that helps stop bleeding). However, these tests are only effective during an episode of FMF, and they return to normal or near normal when an episode ends.

Urinary examination may reveal excess loss of a protein called albumin, which can be indicative of kidney disease.

A diagnosis of FMF can be confirmed by molecular genetic testing, which can identify the characteristic MEFV gene mutation that causes the disorder. Molecular genetic testing is available through commercial and academic research laboratories.


There is no cure for FMF, but there are effective treatments. Specific treatments are aimed at the specific symptoms apparent in each individual. Many individuals are treated with a medication called colchicine, a complex compound that reduces inflammation. Most affected individuals who take the medication show a marked improvement in the duration and frequency of episodes. Colchicine is also effective in preventing the accumulation of amyloid in the kidneys. However, colchicine requires strict daily adherence and it does not treat an episode once an episode has begun. Therefore, increasing the dosage during an episode is not beneficial. On July 30, 2009, the U.S. Food and Drug Administration (FDA) approved the oral colchicine product Colcrys to treat FMF.

Nonsteroidal anti-inflammatory drugs (NSAIDs) and pain medications (analgesics) can be used to treat individuals during a febrile or inflammatory episode. NSAIDs are also used to treat joint and muscle pain, which do not respond to colchicine.

Colchicine can prevent the development of renal amyloidosis, even if it is ineffective in treating FMF attacks. Early stage renal amyloidosis is reversible. Some individuals with FMF and amyloidosis eventually develop end stage renal disease (ESRD), ultimately requiring a kidney transplant. Initially, an affected individual may undergo dialysis. Dialysis is a procedure in which a machine is used to perform some of the functions of the kidney - filtering waste products from the bloodstream, helping to control blood pressure and helping to maintain proper levels of essential chemicals such as potassium. ESRD is not reversible so individuals will eventually require a kidney transplant. The rate of progressive of kidney dysfunction to ESRD can vary greatly from one individual to another. With the advent of colchicine therapy, the number of individuals with FMF requiring a kidney transplant has dropped. Most individuals with FMF who ultimately require a kidney transplant were unable to take colchicine or failed to be compliant with the required daily dosage.

Genetic counseling may be of benefit for affected individuals and their families. Any additional treatment is symptomatic and supportive.

Investigational Therapies

Some individuals who have not responded to colchicine therapy have been treated with anakinra (Kineret). Anakinra is an interkeukin-1 receptor antagonist; it blocks the activity of interleukin-1. Initial reports have suggested that this drug is a safe and effective alternative for individuals who do not respond to colchicine. More research is necessary to determine the long-term safety and effectiveness of anakinra for individuals with FMF.

Two drugs that have been approved by the FDA for the treatment of autoinflammatory disorders such as cold autoinflammatory syndrome are being studied as potential therapies for individuals with FMF. The drugs are rilonacept (Arcalyst) by Regeneron Pharmaceuticals and canakinumab (Ilaris) by Novartis Pharmaceuticals. More research is necessary to determine the long-term safety and effectiveness of these medications in the treatment of individuals with FMF.

Additional drugs that have been used in individuals who are unresponsive to colchicine include thalidomide, etanercept, interferon alpha, and sulphasalazine. More research is necessary to determine the long-term safety and effectiveness of these potential treatments for FMF.

Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. government funding, and some supported by private industry, are posted on this government web site.

For information about trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:

Toll-free: (800) 411-1222

TTY: (866) 411-1010

Email: prpl@cc.nih.gov

For information about clinical trials sponsored by private sources, in the main, contact:




El-Shanti H. Familial Mediterranean Fever. In: NORD Guide to Rare Disorders. Lippincott Williams & Wilkins. Philadelphia, PA. 2003:19.


Savic S, Dickie LJ, Battellino M, McDermott MF. Familial Mediterranean fever and related periodic fever syndromes/autoinflammatory diseases. Curr Opin Rheumatol. 2012;24:103-112. http://www.ncbi.nlm.nih.gov/pubmed/22089100

Livneh A. Familial Mediterranean fever: a continuously challenging disease. IMAJ. 2011;13:197-198. http://www.ncbi.nlm.nih.gov/pubmed/21598803

Henderson C, Goldback-Mansky R. Monogenic autoinflammatory diseases: new insights into clinical aspects and pathogenesis. Curr Opin Rheumatol. 2010;22:567-578. http://www.ncbi.nlm.nih.gov/pubmed/20671522

Gillepsie J, Mathews R, McDermott MF. Rilonacept in the management of cryopyrin-associated periodic syndromes (CAPS). J Inflamm Res. 2010;3:1-8. http://www.ncbi.nlm.nih.gov/pubmed/22096352

De Sanctis S, Nozzi M, Del Torto M, et al. Autoinflammatory syndromes: diagnosis and management. Ital J Pediatr. 2010;36:57. http://www.ncbi.nlm.nih.gov/pubmed/20813071

Ben-Chetrit E, Touitou I. Familial Mediterranean fever in the world. Arthritis Rheum. 2009;61:1447-1453. http://www.ncbi.nlm.nih.gov/pubmed/19790133

Booty MG, Chae JJ, Masters SL, et al. Familial Mediterranean fever with a single MEFV mutation: where is the second hit? Arthritis Rheum. 2009;60:1851-1861. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2753538/?tool=pubmed

Chae JJ, Aksentijevich I, Kastner DL. Advances in the understanding of familial Mediterranean fever and possibilities for targeted therapy. Br J Haematol. 2009;146:467-478. http://www.ncbi.nlm.nih.gov/pubmed/19466978

Kone-Paut I, Hentgen V, Guillaume-Czitron S, et al. The clinical spectrum of 94 patients carrying a single mutated MEFV allele. Rheumatology. 2009;48:840-842. http://www.ncbi.nlm.nih.gov/pubmed/19465590

Milhavet F, Cuisset L, Hoffman HM, et al. The infevers autoinflammatory mutation online registry: update with new genes and functions. Hum Mutat. 2008;29:803-808. http://www.ncbi.nlm.nih.gov/pubmed/18409191

El-Shanti H, Majeed HA, El-Khateeb M. Familial Mediterranean fever in Arabs. Lancet. 2006;367:1016-1024. http://www.ncbi.nlm.nih.gov/pubmed/16564365


Shinawi M, Scaglia F. Familial Mediterranean Fever. Emedicine Journal, November 8, 2010. Available at: http://emedicine.medscape.com/article/952254-overview#aw2aab6b3 Accessed on: May 30, 2012.

Shohat M, Halpern GJ. Familial Mediterranean Fever. Updated:04/26/2012. In: GeneReviews at GeneTests: Medical Genetics Information Resource (database online). Copyright, University of Washington, Seattle. 1997-2003. Available at http://www.genetests.org.

National Genome Research Institute. Learning About Familial Mediterranean Fever. October 13, 2011. Available at: http://www.genome.gov/12510679 Accessed on: May 30, 2012.

Mayo Clinic for Medical Education and Research. Familial Mediterranean Fever. July 22, 2010. Available at: http://www.mayoclinic.com/health/familial-mediterranean-fever/DS00766 Accessed On: May 30, 2012.

Touitou I. Familial Mediterranean Fever. Orphanet encyclopedia, December 2004. Available at: http://www.orpha.net/data/patho/Pro/en/MediterraneanFeverFamilial-FRenPro920.pdf Accessed on: May 30, 2012.


March of Dimes Birth Defects Foundation

1275 Mamaroneck Avenue

White Plains, NY 10605

Tel: (914)997-4488

Fax: (914)997-4763

Tel: (888)663-4637

Email: Askus@marchofdimes.com

Internet: http://www.marchofdimes.com

NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases

Information Clearinghouse

One AMS Circle

Bethesda, MD 20892-3675


Tel: (301)495-4484

Fax: (301)718-6366

Tel: (877)226-4267

TDD: (301)565-2966

Email: NIAMSinfo@mail.nih.gov

Internet: http://www.niams.nih.gov/

Genetic and Rare Diseases (GARD) Information Center

PO Box 8126

Gaithersburg, MD 20898-8126

Tel: (301)251-4925

Fax: (301)251-4911

Tel: (888)205-2311

TDD: (888)205-3223

Internet: http://rarediseases.info.nih.gov/GARD/

Madisons Foundation

PO Box 241956

Los Angeles, CA 90024

Tel: (310)264-0826

Fax: (310)264-4766

Email: getinfo@madisonsfoundation.org

Internet: http://www.madisonsfoundation.org

NOMID Alliance

P.O. Box 590354

San Francisco, CA 94118

Tel: (415)831-8782

Email: karen.nomidalliance.org@gmail.com

Internet: http://www.nomidalliance.net

International Society for Systemic Auto-Inflammatory Diseases

Unité médicale des maladies auto-inflammatoires (Reference Center)

Laboratoire de génétique

Hôpital Arnaud de Villeneuve

Montpellier Cedex 5



Tel: 33467335859

Fax: 33467335867

Email: isabelle.touitou@igh.cnrs.fr

Internet: http://fmf.igh.cnrs.fr/ISSAID/

For a Complete Report

This is an abstract of a report from the National Organization for Rare Disorders, Inc.® (NORD). Cigna members can access the complete report by logging into myCigna.com. For non-Cigna members, a copy of the complete report can be obtained for a small fee by visiting the NORD website. The complete report contains additional information including symptoms, causes, affected population, related disorders, standard and investigational treatments (if available), and references from medical literature. For a full-text version of this topic, see http://www.rarediseases.org/search/rdblist.html.

This information does not replace the advice of a doctor. Healthwise, Incorporated disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use . How this information was developed to help you make better health decisions.

Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.